thiotepa has been researched along with Encephalopathy, Toxic in 4 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We previously demonstrated that Busulfan-Thiotepa (Bu-Thio) and ASCT effectively treated patients with locally relapsed medulloblastoma after surgery and conventional chemotherapy." | 9.11 | High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. ( Benhamou, E; Couanet, D; Fillipini, B; Grill, J; Habrand, JL; Hartmann, O; Kalifa, C; Valteau-Couanet, D, 2005) |
| "We previously demonstrated that Busulfan-Thiotepa (Bu-Thio) and ASCT effectively treated patients with locally relapsed medulloblastoma after surgery and conventional chemotherapy." | 5.11 | High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. ( Benhamou, E; Couanet, D; Fillipini, B; Grill, J; Habrand, JL; Hartmann, O; Kalifa, C; Valteau-Couanet, D, 2005) |
| "Serious neurological adverse events (NAE) have occurred during treatment with high-dose thiotepa regimens of children with high-risk solid tumours." | 1.48 | High-dose thiotepa-related neurotoxicity and the role of tramadol in children. ( Demirdjian, S; Dufour, C; Laplanche, A; Lemare, F; Maritaz, C; Valteau-Couanet, D, 2018) |
| "However, survivors of brain tumors and any survivor who received high-dose neurotoxic treatment reported the lowest rates of achieving milestones of psychosexual development, whereas sexual and relationship status satisfaction were found to be related to relationship status." | 1.46 | Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator. ( Bajwa, RPS; Gerhardt, CA; Hagedoorn, M; Keim, MC; Lehmann, V; Olshefski, RS; Tuinman, MA; Winning, AM, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maritaz, C | 1 |
| Lemare, F | 1 |
| Laplanche, A | 1 |
| Demirdjian, S | 1 |
| Valteau-Couanet, D | 2 |
| Dufour, C | 1 |
| Ferreri, AJ | 1 |
| Cwynarski, K | 1 |
| Pulczynski, E | 1 |
| Ponzoni, M | 1 |
| Deckert, M | 1 |
| Politi, LS | 1 |
| Torri, V | 1 |
| Fox, CP | 1 |
| Rosée, PL | 1 |
| Schorb, E | 1 |
| Ambrosetti, A | 1 |
| Roth, A | 1 |
| Hemmaway, C | 1 |
| Ferrari, A | 1 |
| Linton, KM | 1 |
| Rudà, R | 1 |
| Binder, M | 1 |
| Pukrop, T | 1 |
| Balzarotti, M | 1 |
| Fabbri, A | 1 |
| Johnson, P | 1 |
| Gørløv, JS | 1 |
| Hess, G | 1 |
| Panse, J | 1 |
| Pisani, F | 1 |
| Tucci, A | 1 |
| Stilgenbauer, S | 1 |
| Hertenstein, B | 1 |
| Keller, U | 1 |
| Krause, SW | 1 |
| Levis, A | 1 |
| Schmoll, HJ | 1 |
| Cavalli, F | 1 |
| Finke, J | 1 |
| Reni, M | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Lehmann, V | 1 |
| Tuinman, MA | 1 |
| Keim, MC | 1 |
| Winning, AM | 1 |
| Olshefski, RS | 1 |
| Bajwa, RPS | 1 |
| Hagedoorn, M | 1 |
| Gerhardt, CA | 1 |
| Fillipini, B | 1 |
| Benhamou, E | 1 |
| Grill, J | 1 |
| Kalifa, C | 1 |
| Couanet, D | 1 |
| Habrand, JL | 1 |
| Hartmann, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra[NCT01011920] | Phase 2 | 126 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thiotepa and Encephalopathy, Toxic
| Article | Year |
|---|---|
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System | 2016 |
High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combi | 2005 |
2 other studies available for thiotepa and Encephalopathy, Toxic
| Article | Year |
|---|---|
High-dose thiotepa-related neurotoxicity and the role of tramadol in children.
Topics: Adolescent; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2018 |
Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Cranial Irradiation; Cytarabine | 2017 |